<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Perioperative uses of intravenous opioids: Specific agents</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Perioperative uses of intravenous opioids: Specific agents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Perioperative uses of intravenous opioids: Specific agents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John C Alexander, MD, MBA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Girish P Joshi, MB, BS, MD, FFARCSI</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1854539683"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Intravenous (IV) opioids are commonly used to provide analgesia and supplement sedation during general anesthesia or monitored anesthesia care (MAC), and are the most widely used agents for treatment of acute pain in the immediate postoperative period.</p><p>This topic discusses specific perioperative uses for individual opioid agents, as well as the advantages, disadvantages, drug-drug interactions, dosing, and pharmacokinetics for each of these opioid agents. The occasional use of <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a> to treat postoperative shivering is noted elsewhere. (See  <a class="medical medical_review" href="/z/d/html/94588.html" rel="external">"Perioperative temperature management", section on 'Shivering'</a>.)</p><p>A separate topic reviews typical uses for opioids in the perioperative setting as well as general considerations for opioid dosing and benefits and adverse effects associated with opioid administration in this setting. (See  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations"</a>.)</p><p>Other topics review uses of opioids in other settings (eg, critical care, palliative care, chronic pain management). (See  <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain"</a> and  <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">"Pain control in the critically ill adult patient", section on 'Opioid analgesics'</a>.)</p><p class="headingAnchor" id="H4278730478"><span class="h1">OVERVIEW OF DOSING AND USES OF OPIOIDS</span><span class="headingEndMark"> — </span>Perioperative uses of opioids are discussed in detail in a separate topic. (See  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Perioperative uses of opioids'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Recommended doses of IV opioids for various uses in the perioperative setting and pharmacokinetic considerations for these agents are summarized in the tables  (<a class="graphic graphic_table graphicRef111779" href="/z/d/graphic/111779.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef111780" href="/z/d/graphic/111780.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General anesthesia and monitored anesthesia care</strong> – We typically employ a short-acting opioid (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>) for bolus dosing during general anesthesia or monitored anesthesia care (MAC). <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">Remifentanil</a> is most suitable for continuous infusion during a total intravenous anesthesia (TIVA) technique, particularly when the intensity of surgical stimulation will vary during the procedure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative analgesia</strong> – For postoperative analgesia, we typically administer a long-acting opioid (eg, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> or <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>) approximately 20 to 30 minutes before anticipated tracheal extubation, with dose reduction if non-opioid analgesic agents or techniques are coadministered.</p><p></p><p class="headingAnchor" id="H2510014319"><span class="h1">FENTANYL</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a> is a synthetic derivative of <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> in the phenylpiperidine family of opioid agents. It is the most commonly used intraoperative opioid agent for bolus dosing during general anesthesia or monitored anesthesia care (MAC). Fentanyl is 50 to 100 times more potent than morphine. Fentanyl is highly lipophilic, which allows rapid penetration of the blood-brain barrier and rapid onset of action (four to six minutes), although maximal analgesic and respiratory depressant effects of fentanyl may not be evident for several minutes. Fentanyl has the longest duration of action of the agents in the phenylpiperidine family.</p><p class="headingAnchor" id="H1538854576"><span class="h2">Uses and dosing</span><span class="headingEndMark"> — </span>Recommended doses of IV <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> are presented in the table  (<a class="graphic graphic_table graphicRef111779" href="/z/d/graphic/111779.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1747917631"><span class="h3">General anesthesia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preinduction</strong> – <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a> may be administered in 25 mcg increments in selected patients complaining of pain or requiring a regional anesthetic procedure during the preinduction period; the total preinduction dose is typically ≤100 mcg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction </strong>– During induction of general anesthesia, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> is often selected as the IV opioid adjuvant agent (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Induction'</a>). A typical dose is 25 to 100 mcg (or 0.5 to 1 mcg/kg), administered as a bolus or in divided doses three to five minutes before injection of the sedative-hypnotic induction agent [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Opioids'</a>.)</p><p></p><p class="bulletIndent1">In selected patients with poor myocardial function, a high dose of <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> (eg, 10 to 25 mcg/kg) may be employed to induce general anesthesia if the patient will remain intubated with controlled ventilation for several postoperative hours (eg, after a cardiac surgical procedure). (See  <a class="medical medical_review" href="/z/d/html/126473.html" rel="external">"Anesthesia for cardiac surgery: General principles", section on 'Higher-dose opioid technique'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance</strong> – (See  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Analgesic component: Opioid agents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supplemental agent for inhalation technique </strong>– <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a> is often selected to provide supplemental analgesia during maintenance of general anesthesia with an inhalation technique. Typical adult bolus doses are 25 to 50 mcg, administered as needed to provide analgesia and to avoid or treat hemodynamic responses to surgical stimuli (eg, tachycardia, hypertension) [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Analgesic component for a TIVA technique</strong> – <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a> may be selected to provide the analgesic component of a total intravenous anesthesia (TIVA) technique, but has a prolonged context-sensitive half-time (the time in minutes required for a 50 percent decrease in effect-site concentration after the infusion is discontinued); this leads to delayed recovery  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>) [<a href="#rid2">2-4</a>]. Therefore, a fentanyl infusion is not as ideal for TIVA as some other opioid agents (eg, <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>, <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>) if extubation is planned at the end of the surgical procedure. (See <a class="local">'Remifentanil'</a> below and <a class="local">'Sufentanil'</a> below.)</p><p></p><p class="bulletIndent2">Occasionally <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> may be selected for infusion during a TIVA technique (eg, when a period of controlled postoperative ventilation is planned). A typical dose is 1 to 2 mcg/kg per hour, with adjustments as needed to deepen analgesia to avoid or treat hemodynamic responses to surgical stimuli. Timing discontinuation of the fentanyl infusion is challenging when delayed emergence and respiratory depression are undesirable at the end of the surgical procedure (see <a class="local">'Pharmacokinetics'</a> below). Alternatively, fentanyl can be administered in incremental boluses as part of a TIVA technique to deepen analgesia or treat hemodynamic responses to surgical stimuli.</p><p></p><p class="headingAnchor" id="H1340351306"><span class="h3">Monitored anesthesia care</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a> is typically used in small, intermittent IV bolus doses of 25 to 50 mcg during MAC. (See  <a class="medical medical_review" href="/z/d/html/94529.html" rel="external">"Monitored anesthesia care in adults", section on 'Opioids'</a>.)</p><p></p><p class="headingAnchor" id="H221485876"><span class="h3">Treatment of acute postoperative pain</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a> may be administered in the post-anesthesia care unit (PACU) in doses of 25 to 50 mcg every five minutes for moderate acute pain or in doses of 50 to 100 mcg every two to five minutes for severe acute pain, until the pain is relieved or unwanted adverse effects become evident (eg, respiratory depression, sedation, oxygen saturation &lt;95 percent, hypotension). After initial pain control, the clinician should reassess the postoperative analgesic regimen to determine the best options for further management. (See  <a class="medical medical_review" href="/z/d/html/134254.html" rel="external">"Use of opioids for postoperative pain control", section on 'Treating pain in the postanesthesia care unit (PACU)'</a>.)</p><p class="headingAnchor" id="H2315056331"><span class="h2">Advantages</span><span class="headingEndMark"> — </span>In addition to the benefits of most opioids (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>), <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> has the following specific advantages:</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid onset (three to five minutes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High potency (100 times compared with <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Effective analgesia for surgical trauma causing severe pain during the intraoperative or immediate postoperative period, due to a prolonged duration of action.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Minimal effect on myocardial or hemodynamic function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of histamine-releasing properties; thus, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> is appropriate for patients with bronchospasm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Generally lower cost compared with <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>, <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a>, and <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>.</p><p></p><p class="headingAnchor" id="H2081323152"><span class="h2">Disadvantages</span><span class="headingEndMark"> — </span>In addition to the potential adverse effects of most opioids (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Prevention and management of adverse opioid effects'</a>), <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> has the following specific disadvantages:</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged context-sensitive half-time when administered as an infusion  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>). For example, after infusion of <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> for 200 minutes, approximately 200 more minutes are necessary to achieve a 50 percent decrease in its effect-site concentration. Thus, emergence from general anesthesia may be delayed after a fentanyl infusion. For this reason, we usually avoid a fentanyl infusion for surgical cases of short or intermediate duration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Brief self-limiting coughing that occasionally occurs after bolus dosing [<a href="#rid5">5,6</a>].</p><p></p><p class="headingAnchor" id="H3028732836"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span>In addition to synergistic effects with coadministration of <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> and other anesthetic agents (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>), possible interactions specific for fentanyl include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serotonergic agents</strong> – Coadministration of <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) may increase risk for serotonin syndrome  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 3</a>). Management is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CYP3A4 inhibitors</strong> – Administration of CYP3A4 inhibitors such as <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>, or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> may increase plasma levels of <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> since it is metabolized through cytochrome 3A4 [<a href="#rid7">7,8</a>]. Specific interactions may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>. Reduction of the fentanyl dose may be necessary when such agents have been administered to avoid adverse opioid effects such as respiratory depression.</p><p></p><p class="headingAnchor" id="H3796241787"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Pharmacokinetics for <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> are summarized in the table  (<a class="graphic graphic_table graphicRef111780" href="/z/d/graphic/111780.html" rel="external">table 2</a>).</p><p><a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a> is highly lipophilic, with rapid distribution to highly perfused tissues (eg, brain, heart, kidney, and gastrointestinal tract). Initial equilibration time is six minutes, with a slower redistribution to muscle and fat [<a href="#rid9">9</a>].</p><p><a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a> has a short duration of action when administered as a bolus dose (30 to 45 minutes) due to its high lipid solubility and redistribution to fatty tissue  (<a class="graphic graphic_figure graphicRef109504" href="/z/d/graphic/109504.html" rel="external">figure 2</a>). However, fentanyl has a prolonged context-sensitive half-time when administered as an infusion, which increases with duration of infusion  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>). Also, stores in muscle and fat are mobilized after discontinuation of an infusion, potentially contributing to prolonged sedation.</p><p><a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a> has a high hepatic extraction ratio of 0.8 to 1.0 such that hepatic blood flow determines the rate of its metabolism. In the liver, fentanyl is metabolized by cytochrome CYP3A4 to norfentanyl, an inactive metabolite that is excreted in the urine. Neither renal nor hepatic insufficiency affects fentanyl pharmacokinetics. The elimination half-life is three to six hours.</p><p class="headingAnchor" id="H2238589710"><span class="h1">REMIFENTANIL</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">Remifentanil</a> is an ultrashort-acting <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> derivative in the phenylpiperidine family of opioid agents, with a potency that is one to two times that of fentanyl [<a href="#rid10">10</a>]. Remifentanil is highly lipophilic and has an even more rapid penetration of the blood-brain barrier and more rapid onset of action (one to two minutes) than fentanyl, <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>, or <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a>. It also has a uniquely short duration of action (5 to 10 minutes after cessation of infusion) because metabolism occurs through esterases located in plasma, red blood cells, and interstitial tissues [<a href="#rid2">2,11-13</a>]. Remifentanil administration as an infusion is the most commonly employed agent for infusion during total intravenous anesthesia (TIVA).</p><p class="headingAnchor" id="H132996737"><span class="h2">Uses and dosing</span><span class="headingEndMark"> — </span>Recommended doses of <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> are presented in the table  (<a class="graphic graphic_table graphicRef111779" href="/z/d/graphic/111779.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1000241909"><span class="h3">General anesthesia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remifentanil</strong><strong> intubation technique</strong> – (See  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Remifentanil intubation technique'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Analgesic component for a TIVA technique </strong>– Among the IV opioids, a <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> infusion is the most suitable agent for a TIVA technique, particularly when the intensity of surgical stimulation varies during the procedure. Remifentanil is typically administered in combination with a <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> infusion since both agents have a short half-life and rapid elimination. Thus, recovery is rapid [<a href="#rid4">4</a>]. For procedures of short to intermediate duration with moderate to intense surgical stimulation, this combination of remifentanil and propofol infusions usually provides satisfactory anesthesia and absence of patient movement. Since the analgesic effect of remifentanil is rapidly terminated after stopping the infusion, its use is most ideal in procedures that incur little or no postoperative pain. (See  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Analgesic component: Opioid agents'</a>.)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">Remifentanil</a> is infused at 0.05 to 0.3 mcg/kg per minute beginning during or shortly after induction to maintain anesthesia for a TIVA technique [<a href="#rid14">14</a>]. We do not usually employ a loading dose since the pharmacokinetics of remifentanil allow attainment of a steady state without loading. Some clinicians do elect to administer a loading dose, typically 0.5 to 1 mcg/kg over 60 to 90 seconds before starting the continuous infusion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supplemental agent for inhalation technique </strong>– <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">Remifentanil</a> may be employed as an adjuvant agent during an inhalation anesthetic technique. Remifentanil infusion at 0.05 to 0.3 mcg/kg per minute improves tolerance to intensely painful surgical stimuli and decreases the required dose of the potent volatile agent [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remifentanil</strong><strong> extubation technique</strong> – (See  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Remifentanil extubation technique'</a>.)</p><p></p><p class="headingAnchor" id="H3517788215"><span class="h3">Monitored anesthesia care</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">Remifentanil</a> may be administered as an infusion during monitored anesthesia care (MAC), with or without initial or intermittent bolus doses. Details regarding this use are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/94529.html" rel="external">"Monitored anesthesia care in adults", section on 'Opioids'</a>.)</p><p class="headingAnchor" id="H91208896"><span class="h2">Advantages</span><span class="headingEndMark"> — </span>In addition to the benefits of most opioids (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>), <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> has the following specific advantages:</p><p class="bulletIndent1"><span class="glyph">●</span>Fastest onset of action compared with all other opioids (one to two minutes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid attainment of steady state after a bolus dose  (<a class="graphic graphic_figure graphicRef109503" href="/z/d/graphic/109503.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid offset due to a very short context-sensitive half-time after administration as an infusion (approximately three minutes), regardless of the duration of infusion  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>) [<a href="#rid17">17</a>]. This allows rapid titration to change anesthetic depth during maintenance, as well as a quick recovery during emergence. (See  <a class="medical medical_review" href="/z/d/html/94537.html" rel="external">"Emergence from general anesthesia", section on 'Discontinue anesthetic agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ideal when early recovery and assessment of neurologic function are necessary, due to its rapid elimination [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unaffected by hepatic or renal insufficiency because it is metabolized by ester hydrolysis in the blood and tissues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible lower incidence of postoperative nausea and vomiting, allowing more rapid discharge from the post-anesthesia care unit (PACU), compared with <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H1567916783"><span class="h2">Disadvantages</span><span class="headingEndMark"> — </span>In addition to the potential adverse effects of most opioids (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Prevention and management of adverse opioid effects'</a>), <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> has the following specific disadvantages:</p><p class="bulletIndent1"><span class="glyph">●</span>Generally higher cost than other opioids, particularly if used for long surgical cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible muscle and chest wall rigidity with rapid administration and/or high doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher incidence of hypotension compared with other opioids [<a href="#rid20">20</a>]. In some cases, this may be due to the greater potency of <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> compared with <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> since remifentanil is often used as if it is equipotent [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible tachyphylaxis during administration [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Need for administration of an alternative analgesic agent or technique during emergence and/or the immediate postoperative period if postoperative pain is anticipated, because the analgesic effect of <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> is terminated within minutes of discontinuing its infusion [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible acute tolerance and opioid-induced hyperalgesia (OIH) after discontinuation of a <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> infusion [<a href="#rid22">22,23</a>]. These adverse effects are dose-dependent and more likely with high doses &gt;0.3 mcg/kg per minute or a cumulative dose &gt;50 mcg/kg [<a href="#rid21">21,24,25</a>]. However, data are inconsistent [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher incidence of postoperative shivering compared with other opioids [<a href="#rid27">27</a>]. Treatment of postoperative shivering is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/94588.html" rel="external">"Perioperative temperature management", section on 'Shivering'</a>.)</p><p></p><p class="headingAnchor" id="H14194751"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span>Except for the synergistic effects with coadministration of other anesthetic agents (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>), <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> has minimal drug interactions due to its rapid metabolism.</p><p class="headingAnchor" id="H4207575004"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Pharmacokinetics for <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> are summarized in the table  (<a class="graphic graphic_table graphicRef111780" href="/z/d/graphic/111780.html" rel="external">table 2</a>).</p><p><a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">Remifentanil</a> is highly lipophilic, with extremely rapid distribution to highly perfused tissues (eg, brain, heart, kidney, and gastrointestinal tract). Initial equilibration time is one to two minutes.</p><p><a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">Remifentanil</a> has a very short duration of action, with a context-sensitive half-time of approximately three minutes and a pharmacodynamic offset at approximately five minutes  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>) [<a href="#rid17">17</a>]. It is metabolized by nonspecific plasma esterases in the plasma, red blood cells, and interstitial tissue to an inactive metabolite (remifentanil acid), which is subsequently excreted unchanged in the urine. Elimination half-life for remifentanil is 10 to 20 minutes [<a href="#rid11">11,13,28</a>]. There is no evidence of accumulation in patients with renal and/or hepatic dysfunction.</p><p class="headingAnchor" id="H2872017680"><span class="h1">SUFENTANIL</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">Sufentanil</a> is a phenylpiperidine opioid that is approximately 10 times more potent than <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> and is used in similar settings [<a href="#rid2">2,3,29</a>]. Like fentanyl, sufentanil is highly lipophilic with rapid onset (three to five minutes) and low cost compared with newer synthetic opioids such as <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>.</p><p class="headingAnchor" id="H3627568837"><span class="h2">Uses and dosing</span><span class="headingEndMark"> — </span>Recommended doses of <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a> are presented in the table  (<a class="graphic graphic_table graphicRef111779" href="/z/d/graphic/111779.html" rel="external">table 1</a>) [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H3918424011"><span class="h3">General anesthesia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction</strong> – During induction of general anesthesia, <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a> is often selected as the IV opioid adjuvant agent (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Induction'</a>). A typical dose is 0.1 to 0.2 mcg/kg, administered in divided doses three to five minutes prior to the sedative-hypnotic induction agent. (See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Opioids'</a>.)</p><p></p><p class="bulletIndent1">In selected patients with poor myocardial function, a high dose of <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a> (eg, 1 to 3 mcg/kg) may be employed to induce general anesthesia if the patient will remain intubated with controlled ventilation for several postoperative hours (eg, after a cardiac surgical procedure). (See  <a class="medical medical_review" href="/z/d/html/126473.html" rel="external">"Anesthesia for cardiac surgery: General principles", section on 'Higher-dose opioid technique'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supplemental agent for inhalation technique</strong> – During maintenance of general anesthesia with an inhalation technique, <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a> is often the selected adjuvant opioid agent. Typically, 5 to 10 mcg bolus doses are administered as necessary to provide supplemental analgesia or to treat hemodynamic responses to surgical stimulation (eg, tachycardia, hypertension) [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Analgesic component for a TIVA technique </strong>– <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">Sufentanil</a> may be selected to provide the analgesic component of general anesthesia with a total intravenous anesthesia (TIVA) technique, particularly in cases with a prolonged duration (eg, cardiac and neurologic surgery) when rapid emergence is not needed. Typically, 5 to 10 mcg bolus doses or a continuous infusion at 0.05 to 0.15 mcg/kg per hour (or 0.0008 to 0.0025 mcg/kg per minute) is administered. Although sufentanil has a shorter context-sensitive half time than <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, it is longer than that of <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>), with a slower return of neurocognitive function. However, unlike remifentanil, sufentanil has the advantage of providing an analgesic effect into the postoperative period. (See  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Analgesic component: Opioid agents'</a>.)</p><p></p><p class="headingAnchor" id="H4238404223"><span class="h2">Advantages</span><span class="headingEndMark"> — </span>In addition to the benefits of most opioids (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>), <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a> has the following specific advantages:</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid onset (three to five minutes for peak effect).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High potency (5 to 10 times more potent than <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Shorter context-sensitive half time compared with <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>). Thus, recovery is more rapid after infusions lasting several hours, compared with equipotent doses of fentanyl [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low cost compared with <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ideal for longer procedures when continuous opioid administration and a postoperative analgesic effect are desirable.</p><p></p><p class="headingAnchor" id="H2965830065"><span class="h2">Disadvantages</span><span class="headingEndMark"> — </span>Potential adverse effects of <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a> are similar to those of other lipophilic opioids [<a href="#rid32">32-34</a>]. (See  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Prevention and management of adverse opioid effects'</a>.)</p><p class="headingAnchor" id="H4213516584"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span>Synergistic effects occur with coadministration of <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a> and other anesthetic agents. (See  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>.)</p><p class="headingAnchor" id="H1069851857"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Pharmacokinetics for <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a> are summarized in the table  (<a class="graphic graphic_table graphicRef111780" href="/z/d/graphic/111780.html" rel="external">table 2</a>).</p><p><a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">Sufentanil</a> is rapidly distributed to highly perfused tissues with an initial equilibration time of six minutes. The context-sensitive half time is shorter than that for <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, but longer than for <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>). For example, after continuous infusion of sufentanil for 200 minutes, a 50 percent decrease in its effect-site concentration occurs in 30 to 45 minutes, compared with approximately 200 minutes for fentanyl or four minutes for remifentanil.</p><p><a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">Sufentanil</a> is metabolized in both the small intestine and liver, and is excreted in the urine. Its elimination half-life is two to four hours [<a href="#rid11">11,30,35</a>].</p><p class="headingAnchor" id="H1674915313"><span class="h1">ALFENTANIL</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">Alfentanil</a> is a phenylpiperidine opioid that is approximately three times less potent than <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> and is used in similar settings [<a href="#rid2">2,3,29</a>]. It is highly lipophilic, allowing very rapid penetration of the blood-brain barrier and rapid onset of action (one to three minutes). The cost for alfentanil is intermediate between that of <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> and <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>.</p><p class="headingAnchor" id="H3073844444"><span class="h2">Uses and dosing</span><span class="headingEndMark"> — </span>Recommended doses of <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a> are presented in the table  (<a class="graphic graphic_table graphicRef111779" href="/z/d/graphic/111779.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2682843349"><span class="h3">General anesthesia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction</strong> – During induction of general anesthesia, <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a> is occasionally selected as the IV opioid adjuvant agent (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Induction'</a>). A typical adult dose is 500 mcg administered as a bolus (which may be repeated until the desired effect is achieved), or 50 to 100 mcg/kg administered in divided doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance</strong> – During maintenance of general anesthesia with an inhalation technique, <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a> is occasionally selected to provide supplemental analgesia. Typically, small IV doses of 500 mcg are titrated as necessary to provide analgesia and to avoid or treat hemodynamic responses to surgical stimuli (eg, tachycardia, hypertension) [<a href="#rid2">2</a>]. Alfentanil has a context-sensitive half time similar to that for <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>), and is suitable for cases lasting longer than six hours when a rapid decrease in opioid effect is desirable [<a href="#rid36">36</a>]. The dose range for continuous infusion of alfentanil is 0.5 to 1.5 mcg/kg per minute. (See  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Analgesic component: Opioid agents'</a>.)</p><p></p><p class="headingAnchor" id="H1963913815"><span class="h2">Advantages</span><span class="headingEndMark"> — </span>In addition to the benefits of most opioids (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>), <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a> has the following specific advantages:</p><p class="bulletIndent1"><span class="glyph">●</span>Very rapid onset of action (one to three minutes) which is faster than <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> but slightly less rapid than <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid attainment of steady state after a bolus dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Shorter context-sensitive half time compared with <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> (similar to that for <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>)  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>).</p><p></p><p class="headingAnchor" id="H4185994383"><span class="h2">Disadvantages</span><span class="headingEndMark"> — </span>In addition to the potential adverse effects of most opioids (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Prevention and management of adverse opioid effects'</a>), a major disadvantage for <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a> is focal activation of the cerebral cortex in susceptible patients, which produces seizure-like electrical activity that can be identified with electroencephalogram monitoring. Thus, alfentanil is avoided in patients with risk factors for seizures.</p><p class="headingAnchor" id="H2592650103"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span>Synergistic effects occur with coadministration of <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a> and other anesthetic agents (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>). Similar to <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, interactions with CYP3A4 inhibitors such as <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> may increase plasma levels of alfentanil since it is metabolized through cytochrome 3A4 [<a href="#rid37">37</a>]. Specific interactions may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p class="headingAnchor" id="H2632037525"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Pharmacokinetics for <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a> are summarized in the table  (<a class="graphic graphic_table graphicRef111780" href="/z/d/graphic/111780.html" rel="external">table 2</a>).</p><p><a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">Alfentanil</a> is rapidly distributed to highly perfused tissues with an initial equilibration time of one to three minutes [<a href="#rid36">36</a>]. Its context-sensitive half time is comparable to that of <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a> (ie, 30 to 45 minutes).</p><p>Hepatic metabolism of <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a> is less predictable than for <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> and <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a> due to significant inter-individual variability in activity of hepatic CYP3A4 (the enzyme primarily responsible for biotransformation of alfentanil). Elimination half-life is typically 1.5 to 2 hours.</p><p class="headingAnchor" id="H1524820226"><span class="h1">MORPHINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">Morphine</a> is the prototype opioid agent; it is approximately 100 to 200 times less potent than <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> [<a href="#rid38">38</a>]. It is a phenanthrene opioid that is less lipophilic than the synthetic opioids (eg, fentanyl, <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>, <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>, <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a>), which results in slower onset of action compared with other opioids (within 5-10 minutes) due to poor penetration of the blood-brain barrier [<a href="#rid39">39</a>]. However, morphine has a long analgesic duration of four to five hours. For this reason, it is often selected to preemptively and/or urgently control postoperative pain.</p><p class="headingAnchor" id="H865175884"><span class="h2">Uses and dosing</span><span class="headingEndMark"> — </span>Recommended doses of IV <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> are presented in the table  (<a class="graphic graphic_table graphicRef111779" href="/z/d/graphic/111779.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2957206471"><span class="h3">General anesthesia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance </strong>– Bolus dosing of <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> during the maintenance phase of anesthesia is less common since the development of shorter-acting IV opioids (eg, <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>, <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a>, <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>). If selected, small IV bolus doses of morphine 1 to 2 mg are titrated as necessary [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Analgesic component: Opioid agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergence</strong> – For patients undergoing a major surgical procedure who have received a non-opioid analgesic agent (eg, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, nonsteroidal anti-inflammatory drug [NSAID]) and/or technique (eg, a regional anesthetic), small doses of IV <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> may be administered in 1 to 2 mg increments (up to 0.05 to 0.1 mg/kg ideal body weight) beginning approximately 15 to 20 minutes prior to tracheal extubation. Patients who did not receive a non-opioid analgesic agent or technique may require a larger upper range for morphine dosing in this setting (ie, 0.1 to 0.2 mg/kg ideal body weight) to provide adequate analgesia. Doses are decreased for older patients &gt;65 years of age and those with comorbidities (eg, hepatic insufficiency) due to the higher risk of adverse effects in such patients [<a href="#rid41">41,42</a>].</p><p></p><p class="headingAnchor" id="H1397549578"><span class="h3">Treatment of acute postoperative pain</span><span class="headingEndMark"> — </span>As noted above, for postoperative analgesia, one can administer a long-acting opioid such as IV <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> approximately 20 to 30 minutes before anticipated tracheal extubation. In the post-anesthesia care unit (PACU), dosing for acute pain is 1 to 3 mg every five minutes until pain is relieved or unwanted adverse effects become evident (eg, respiratory depression, sedation, oxygen saturation &lt;95 percent, hypotension) [<a href="#rid43">43</a>]. After initial pain control, 2 to 4 mg IV every three hours is typically needed. (See  <a class="medical medical_review" href="/z/d/html/134254.html" rel="external">"Use of opioids for postoperative pain control", section on 'Treating pain in the postanesthesia care unit (PACU)'</a>.)</p><p class="headingAnchor" id="H1092273810"><span class="h2">Advantages</span><span class="headingEndMark"> — </span>In addition to the benefits of most opioids (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>), <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> has the following specific advantages:</p><p class="bulletIndent1"><span class="glyph">●</span>Low cost and wide availability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged duration of action (four to six hours). This is an advantage if severe postoperative pain is anticipated.</p><p></p><p class="headingAnchor" id="H598229408"><span class="h2">Disadvantages</span><span class="headingEndMark"> — </span>In addition to the potential adverse effects of most opioids (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Prevention and management of adverse opioid effects'</a>), <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> has the following specific disadvantages:</p><p class="bulletIndent1"><span class="glyph">●</span>Slower onset of analgesia (within 20 minutes) and slower time to peak analgesic effect compared with the synthetic opioids (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>, <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>, <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a>), due to lower lipid solubility and a longer lag time for penetration of the blood-brain barrier.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long context-sensitive half time (approximately 4.5 hours)  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>). Use of <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> as a continuous infusion is generally avoided since it is difficult to titrate when rapid changes in anesthetic depth are necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher incidence of most opioid-related adverse side effects (eg, pruritus, urinary retention, constipation, and nausea), compared with other opioids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Association with histamine release that may result in facial flushing, pruritus, diaphoresis, and hypotension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased tone or spasm of the sphincter of Oddi and the common bile duct, which diminishes biliary and pancreatic secretions and may lead to biliary colic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unsuitable for patients with hemodynamic instability due to possible exacerbation of hypotension by histamine release, as well as persistence of its effects due to a long context-sensitive half time and the mu-receptor-stimulating properties of its morphine-6-glucuronide metabolite. (See <a class="local">'Pharmacokinetics'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unsuitable for patients with renal insufficiency (creatinine clearance less than 30 mL/minute) due to likely accumulation of its renally-excreted, potentially neurotoxic morphine-6-glucuronide metabolite. This metabolite also has mu-receptor-stimulating properties which may prolong the effects of <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> [<a href="#rid44">44,45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cautious use in patients with a history of seizures if renal insufficiency is present, due to neuroexcitation caused by the morphine-6-glucuronide metabolite, with possible occurrence of myoclonus or exacerbation of seizure activity.</p><p></p><p class="headingAnchor" id="H3519032471"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">Morphine</a> has synergistic effects with coadministration of other anesthetic agents. (See  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>.)</p><p class="headingAnchor" id="H4092794772"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Pharmacokinetics for <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> are summarized in the table  (<a class="graphic graphic_table graphicRef111780" href="/z/d/graphic/111780.html" rel="external">table 2</a>).</p><p>Onset of action after administration of an IV dose of <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> is 5-10 minutes, with a peak effect after 15 to 30 minutes [<a href="#rid43">43</a>]. Morphine is primarily metabolized in the liver to glucuronide metabolites, morphine-6-glucuronide and morphine-3-glucuronide; thus, dose is reduced for patients with hepatic insufficiency. Morphine-6-glucuronide produces ongoing analgesia due to mu-receptor-stimulating properties [<a href="#rid45">45</a>].</p><p>The duration of action of intravenous <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> is three to five hours with an elimination half-life of two to four hours, but up to seven hours are required for the elimination half-life of its morphine-6-glucuronide metabolite [<a href="#rid36">36</a>]. Renal elimination is typically complete within 24 hours.</p><p class="headingAnchor" id="H495302102"><span class="h1">HYDROMORPHONE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">Hydromorphone</a> is a phenanthrene opioid that is a semi-synthetic <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> derivative. It is approximately five times more potent than morphine, has a slightly more rapid onset (with a peak effect within 10 minutes after IV administration [<a href="#rid46">46</a>]), and a shorter half-life of 2.4 hours [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H3174743159"><span class="h2">Uses and dosing</span><span class="headingEndMark"> — </span>Recommended doses of <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a> are presented in the table  (<a class="graphic graphic_table graphicRef111779" href="/z/d/graphic/111779.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1742373192"><span class="h3">General anesthesia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance</strong> – <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">Hydromorphone</a> may be the selected opioid to provide supplemental analgesia with either an inhalation anesthetic or a total intravenous anesthesia (TIVA) technique. Typically, small IV bolus doses of hydromorphone 0.25 to 0.5 mg are administered as necessary. (See  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Analgesic component: Opioid agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergence</strong> – We often select small boluses of IV <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a> rather than <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> for administration near the end of surgery if a long-acting opioid will likely be needed to treat postoperative pain that may be severe or prolonged. Small boluses of hydromorphone (eg, 0.01 mg/kg administered typically to a total dose of 0.25 to 1 mg) may be administered approximately 20 to 30 minutes before anticipated tracheal extubation. (See <a class="local">'Uses and dosing'</a> above.)</p><p></p><p class="headingAnchor" id="H4165329643"><span class="h3">Treatment of acute postoperative pain</span><span class="headingEndMark"> — </span>In the post-anesthesia care unit (PACU), dosing for acute pain is 0.2 to 0.5 mg IV every five minutes until pain is relieved or unwanted adverse effects become evident (eg, respiratory depression, sedation, oxygen saturation &lt;95 percent, hypotension). After initial pain control, 0.2 to 0.5 mg IV every three to four hours is typically needed. (See  <a class="medical medical_review" href="/z/d/html/134254.html" rel="external">"Use of opioids for postoperative pain control", section on 'Treating pain in the postanesthesia care unit (PACU)'</a>.)</p><p class="headingAnchor" id="H3199422625"><span class="h2">Advantages</span><span class="headingEndMark"> — </span>In addition to the benefits of most opioids (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>), <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a> has the following specific advantages:</p><p class="bulletIndent1"><span class="glyph">●</span>Low cost and wide availability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Analgesic efficacy that is slightly better than <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> [<a href="#rid47">47,48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged duration of action (three to four hours). Similar to <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, this is an advantage if severe or prolonged postoperative pain is anticipated.</p><p></p><p class="headingAnchor" id="H1548104807"><span class="h2">Disadvantages</span><span class="headingEndMark"> — </span>In addition to the potential adverse effects of most opioids (see  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Prevention and management of adverse opioid effects'</a>), <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a> has the following specific disadvantages:</p><p class="bulletIndent1"><span class="glyph">●</span>Slower onset of analgesia (5 to 10 minutes) and slower time to peak analgesic effect compared with the synthetic agents (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>, <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>, <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a>), due to lower lipid solubility and a longer lag time for penetration of the blood-brain barrier.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long context-sensitive half time (approximately two to three hours)  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>) [<a href="#rid49">49,50</a>]. <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">Hydromorphone</a> is not typically used as a continuous infusion since it is difficult to titrate when rapid changes in anesthetic depth are necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Caution with use in patients with renal insufficiency (creatinine clearance less than 30 mL/minute) due to likely accumulation of its renally-excreted potentially neurotoxic hydromorphone-3-glucuronide metabolite.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cautious use in patients with seizures due to neuroexcitation caused by its hydromorphone-3-glucuronide metabolite, with possible occurrence of myoclonus or exacerbation of seizure activity.</p><p></p><p class="headingAnchor" id="H3854278068"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span>Synergistic effects occur with coadministration of <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a> and other anesthetic agents. (See  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>.)</p><p>Co-administration with strong inducers of drug metabolism such as <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> may reduce plasma concentrations of <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>, thereby lessening its analgesic effect [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H1350065501"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Pharmacokinetics for <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a> are summarized in the table  (<a class="graphic graphic_table graphicRef111780" href="/z/d/graphic/111780.html" rel="external">table 2</a>).</p><p><a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">Hydromorphone</a> is primarily metabolized in the liver; thus, dose is reduced in patients with hepatic insufficiency. Its hydromorphone-3-glucuronide metabolite is renally excreted. Although this metabolite is effectively removed during hemodialysis, it may accumulate and cause neuroexcitation between dialysis treatments [<a href="#rid52">52</a>]. (See <a class="local">'Disadvantages'</a> above.)</p><p class="headingAnchor" id="H2661257793"><span class="h1">METHADONE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> is a synthetic opioid that is unique because of its effects at multiple sites integral to the transmission and modulation of nociceptive signaling. The potency of intravenous methadone is roughly equivalent to that of <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> [<a href="#rid38">38</a>] (see <a class="local">'Morphine'</a> above). Its mechanism of action is via agonism of the mu-opioid receptor as well as antagonist effects at N-methyl-D-aspartate (NMDA) receptors and inhibition of serotonin and norepinephrine reuptake in the central nervous system [<a href="#rid53">53</a>]. The analgesic effect is greater with methadone plus <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> compared with methadone alone, providing evidence that the primary analgesic effect of methadone is via mu-opioid agonism rather than NMDA antagonism [<a href="#rid54">54</a>].</p><p>Onset of analgesia is reported in as little as eight minutes, but duration may extend to 24 to 36 hours when doses exceed the redistribution half-life (approximately 20 mg) [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H1938252653"><span class="h2">Uses and dosing</span></p><p class="headingAnchor" id="H2067754406"><span class="h3">General anesthesia</span><span class="headingEndMark"> — </span>Most studies have used a single IV dose of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> (typically 0.1 to 0.2 mg/kg ideal body weight up to 20 mg total) administered during induction of anesthesia to provide analgesia through the intraoperative and postoperative phases of care [<a href="#rid56">56</a>]. One dose-finding study in short-stay surgical procedures concluded that 0.25 mg/kg was the optimal dose to balance the goals of maximal analgesia and minimal adverse effects [<a href="#rid57">57</a>].</p><p>Randomized trials and meta-analyses in several surgical populations have noted perioperative opioid-sparing effects with such regimens as well as analgesia extending for up to three days [<a href="#rid58">58-65</a>]. One study in patients undergoing complex spine or cardiac surgical procedures noted continued analgesic benefits for up to three postoperative months [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H1267111737"><span class="h3">Acute postoperative pain</span><span class="headingEndMark"> — </span>Due to the extended half-life at higher doses, close observation and monitoring are necessary in the postoperative period if <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> is administered to treat acute postoperative pain, particularly if methadone is administered after induction of general anesthesia (ie, during the intraoperative or early postoperative period). Since peak respiratory depressant effects of a single IV dose of methadone occur within 45 minutes of administration in most patients, administration at induction usually ensures that the patient will remain intubated until after these peak effects have occurred [<a href="#rid55">55</a>]. Although titration of methadone can be done safely in the post-anesthesia care unit (PACU), careful monitoring of sedation status and respiratory rate must be ensured to avoid overdose [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H3184149295"><span class="h2">Advantages</span><span class="headingEndMark"> — </span>Administration of a single dose of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> during induction of general anesthesia can provide analgesia throughout the intraoperative and postoperative periods, resulting in an overall beneficial opioid-sparing effect [<a href="#rid67">67</a>]. Theoretically, the NMDA antagonist and serotonin/norepinephrine effects each contribute to a duration of analgesia that exceeds the elimination half-life, although this hypothesis has not been demonstrated [<a href="#rid68">68,69</a>].</p><p class="headingAnchor" id="H2469081154"><span class="h2">Disadvantages</span></p><p class="bulletIndent1"><span class="glyph">●</span>Potential for postoperative respiratory depression due to a long half-life (see <a class="local">'Pharmacokinetics'</a> below). An observational study noted a 37 percent incidence of respiratory depression (defined as respiratory rate &lt;8 breaths/minute, or need for &gt;2 L per minute of supplemental oxygen to maintain peripheral arterial oxygen saturation [SpO<sub>2</sub>] &gt;96 percent [<a href="#rid70">70</a>]. However, a review of clinical investigations noted no overall increase in adverse respiratory events related to intraoperative <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> administration [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential for prolonged QTc. Dose and chronicity of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> use are associated with development of a prolonged QTc, particularly after long-term treatment of opioid use disorder [<a href="#rid71">71</a>]. Although the effect of a single perioperative dose of methadone on QTc has not been specifically studied, it is prudent to avoid administration of methadone in patients who already have prolonged QTc on their electrocardiogram.</p><p></p><p class="headingAnchor" id="H3947176437"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> is metabolized in the liver by CYP2D6 [<a href="#rid72">72,73</a>]. Medications inducing CYP2D6 (eg, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>) may increase metabolism of methadone, while CYP2D6 inhibitors such as <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, and <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> may reduce metabolism and increase the likelihood of adverse effects [<a href="#rid56">56</a>]. Methadone also interacts with selective serotonin reuptake inhibitors (SSRIs) and may increase serotonin levels.</p><p class="headingAnchor" id="H2338417262"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Pharmacokinetics for intravenous (IV) <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> are summarized in the table  (<a class="graphic graphic_table graphicRef111780" href="/z/d/graphic/111780.html" rel="external">table 2</a>).<strong> </strong>The redistribution half-life of methadone is six minutes, but once dosing exceeds redistribution capacity the elimination half-life (approximately 30 hours) predominately determines the duration of action [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H3127725951"><span class="h1">MEPERIDINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">Meperidine</a> is a synthetic opioid with analgesic effects due to mu-opioid agonism [<a href="#rid74">74</a>]. Meperidine also inhibits reuptake of serotonin and norepinephrine [<a href="#rid75">75</a>], and has local anesthetic effects [<a href="#rid76">76</a>]. It is approximately 10 times less potent than <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H1575781895"><span class="h2">Uses and dosing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment for shivering </strong>– <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">Meperidine</a> 12.5 to 25 mg IV is often used to treat perioperative shivering [<a href="#rid78">78</a>]. Some experts note that other agents and routes of administration (eg, IV <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a>, IV <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, IV or intrathecal <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a>, or intrathecal <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> or <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>) have similar efficacy with fewer side effects [<a href="#rid79">79-81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perioperative/peripartum analgesia</strong> – <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">Meperidine</a> is uncommonly administered in doses of 25 to 50 mg IV (or 50 to 150 mg orally or 25 to 100 mg subcutaneously or intramuscularly), that may be repeated every three to four hours [<a href="#rid82">82</a>]. The maximum recommend dose for adults is &lt;600 mg/day for no more than 48 hours [<a href="#rid83">83</a>].</p><p></p><p class="headingAnchor" id="H1596127013"><span class="h2">Advantages</span></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid onset (&lt;10 minutes) [<a href="#rid84">84</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Generally lower cost compared with <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>, <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a>, and <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a></p><p></p><p class="headingAnchor" id="H1119031361"><span class="h2">Disadvantages</span><span class="headingEndMark"> — </span>Due to high risk of adverse effects and relative lack of efficacy compared with other opioids, <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a> is generally avoided in pediatric patients [<a href="#rid85">85</a>], or for perioperative analgesia or labor pain in parturients [<a href="#rid82">82</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system (CNS) excitatory effects manifesting as anxiety, hyperreflexia, myoclonus, and seizures due to the active metabolite normeperidine [<a href="#rid86">86</a>]. Use of <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a> for infusions or patient-controlled analgesia is not recommended due to risk of metabolite accumulation and toxicity. Furthermore, risk of normeperidine toxicity is increased in renal insufficiency due to reduced excretion [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) due to unpredictable, severe, and sometimes fatal reactions. The mechanism of such reactions is unknown but may be related to preexisting hyperphenylalaninemia. Clinical presentation of these reactions may be similar to serotonin syndrome or acute opioid overdose, with symptoms that include hyperexcitability, convulsions, tachycardia, hyperpyrexia, and hypertension [<a href="#rid88">88</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serotonin and norepinephrine reuptake inhibition, which may contribute to development of serotonin syndrome, particularly if patients are taking selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs)  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 3</a>). Management is discussed separately. (See <a class="local">'Drug-drug interactions'</a> below and  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticholinergic effects causing agitation, confusion, disorientation, visual hallucinations, and memory deficits [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/z/d/html/305.html" rel="external">"Anticholinergic poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible contribution to negative mood [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High abuse potential leading to frequent addiction and diversion [<a href="#rid74">74</a>].</p><p></p><p class="headingAnchor" id="H2279134782"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span>Interactions specific for <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a> include severe reactions in patients taking MAOIs, and possible serotonin syndrome in patients taking SSRIs or SNRIs  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 3</a>), as noted above. (See <a class="local">'Disadvantages'</a> above.)</p><p class="headingAnchor" id="H459766513"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Pharmacokinetics for IV <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a> are summarized in the table  (<a class="graphic graphic_table graphicRef111780" href="/z/d/graphic/111780.html" rel="external">table 2</a>).</p><p>Since <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a> is primarily metabolized in the liver via the P450 cytochrome system, its elimination half-life life is greatly extended in patients with hepatic cirrhosis [<a href="#rid89">89,90</a>]. Normeperidine is the most clinically relevant metabolite, with a variable half-life up to 48 hours; thus, significant accumulation can occur with chronic or repeated use [<a href="#rid84">84,87</a>]. Renal insufficiency reduces excretion of meperidine and its metabolites, leading to accumulation of normeperidine [<a href="#rid87">87</a>]. Compared with meperidine, normeperidine has reduced analgesic properties but enhanced CNS excitability [<a href="#rid91">91,92</a>].</p><p>Intramuscular <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a> has an average half-life of three to four hours, though there is high variability for this route of administration due to interpatient variability in absorption and metabolism [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H3626171150"><span class="h1">NALBUPHINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">Nalbuphine</a> is a phenanthrene synthetic opioid with agonist-antagonist actions commercially available only in an injectable formulation [<a href="#rid93">93</a>]. It is a weak mu-opioid receptor antagonist and kappa-opioid receptor agonist [<a href="#rid94">94</a>]. At sub-analgesic doses, the mu-opioid receptor antagonism is clinically useful for reversing opioid-related adverse effects. At higher doses, the kappa-opioid receptor agonist effects predominate, resulting in analgesia, and is and is equianalgesic to <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>.</p><p class="headingAnchor" id="H2140299286"><span class="h2">Uses and dosing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perioperative analgesia</strong> – <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">Nalbuphine</a> is used to provide postoperative analgesia due to its kappa-opioid receptor agonist action. Usual dosage is 10 mg IV every three to six hours up to 160 mg/day [<a href="#rid93">93,95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of opioid adverse effects </strong>– Sub-analgesic dosing of <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">nalbuphine</a> is used to treat opioid-related adverse effects (eg, pruritus, urinary retention, respiratory depression) without compromising analgesia [<a href="#rid96">96-98</a>]. Doses in the 2.5 to 5 mg range are especially effective in treating opioid-induced pruritus, although this is an off-label use [<a href="#rid99">99</a>].</p><p></p><p class="headingAnchor" id="H640929588"><span class="h2">Advantages</span></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid onset of analgesia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reversal of opioid-related adverse effects without compromising analgesia [<a href="#rid96">96-98</a>]</p><p></p><p class="headingAnchor" id="H3751676243"><span class="h2">Disadvantages</span></p><p class="bulletIndent1"><span class="glyph">●</span>May precipitate opioid withdrawal in opioid tolerant patients taking mu-opioid receptor agonists [<a href="#rid94">94,100</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>May cause respiratory depression similar to <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, but exhibits a ceiling effect such that doses &gt;30 mg do not induce further respiratory depression [<a href="#rid93">93</a>].</p><p></p><p class="headingAnchor" id="H2037536894"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">Nalbuphine</a> has few interactions with other anesthetic agents since it is metabolized by UGT2B7 rather than via the P450 cytochrome system [<a href="#rid94">94,101</a>]. However, as noted above, administration of nalbuphine to patients taking mu-opioid receptor agonists can precipitate opioid withdrawal. (See <a class="local">'Disadvantages'</a> above.)</p><p class="headingAnchor" id="H2297095569"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Pharmacokinetics for IV <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">nalbuphine</a> are also summarized in the table  (<a class="graphic graphic_table graphicRef111780" href="/z/d/graphic/111780.html" rel="external">table 2</a>).</p><p>Onset is rapid (two to three minutes) after IV administration (&lt;15 minutes after subcutaneous or intramuscular administration). Duration of action is three to six hours with an elimination half-life of five hours [<a href="#rid93">93</a>]. <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">Nalbuphine</a> is metabolized in the liver via UGT2B7 with inactive metabolites, with renal clearance [<a href="#rid93">93</a>]. Although dose reduction is recommended in renal insufficiency [<a href="#rid93">93</a>], one study showed little accumulation of an orally administered formulation in dialysis patients [<a href="#rid102">102</a>].</p><p class="headingAnchor" id="H3641821656"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General considerations</strong> (See <a class="local">'Overview of dosing and uses of opioids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing</strong> – Recommended doses of intravenous (IV) opioids used in the perioperative setting and pharmacokinetics of these agents are summarized in the tables  (<a class="graphic graphic_table graphicRef111779" href="/z/d/graphic/111779.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef111780" href="/z/d/graphic/111780.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General anesthesia and monitored anesthesia care</strong> – We typically employ a short-acting opioid (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>) for bolus dosing during general anesthesia or monitored anesthesia care (MAC). <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">Remifentanil</a> is most suitable for continuous infusion during a total intravenous anesthesia (TIVA) technique, particularly when the intensity of surgical stimulation will vary during the procedure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postoperative analgesia</strong> – For postoperative analgesia, we typically administer a long-acting opioid (eg, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> or <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>) approximately 20 to 30 minutes before anticipated tracheal extubation, with dose reduction if non-opioid analgesic agents or techniques are coadministered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fentanyl</strong> – <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a> is the most commonly used intraoperative opioid, typically for bolus dosing during the preinduction, induction, or maintenance phases of general anesthesia (as the analgesic component of a TIVA technique or an adjunct agent during inhalation anesthesia). Fentanyl may also be used during MAC, or for treatment of acute postoperative pain. (See <a class="local">'Nalbuphine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remifentanil</strong> – <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">Remifentanil</a> is an ultra-short-acting <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> derivative that is one to two times more potent than fentanyl, with a more rapid onset of action (one to two minutes) and attainment of steady state  (<a class="graphic graphic_figure graphicRef109503" href="/z/d/graphic/109503.html" rel="external">figure 3</a>), as well as a uniquely short duration of action (5 to 10 minutes after cessation of infusion) because metabolism occurs through esterases located in plasma, red blood cells, and interstitial tissues. A remifentanil infusion is often selected as the analgesic component of a TIVA technique, or is employed during inhalation general anesthesia, or as during a MAC technique. Remifentanil is also used as primary agent during remifentanil intubation or extubation. (See <a class="local">'Remifentanil'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sufentanil</strong> – <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">Sufentanil</a> is approximately ten times more potent than <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> and is used in similar settings. Sufentanil has a low cost compared with <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> and a shorter context-sensitive half time compared with fentanyl allowing for more rapid recovery after infusions lasting several hours  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 1</a>). Thus, sufentanil is ideal for longer procedures when continuous opioid administration and a postoperative analgesic effect are desirable. (See <a class="local">'Sufentanil'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alfentanil</strong> – <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">Alfentanil</a> is approximately three times less potent than <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> and is used in similar settings. It is highly lipophilic, allowing very rapid penetration of the blood-brain barrier and rapid onset of action (one to three minutes). Its cost is intermediate between that of <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> and <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>. (See <a class="local">'Alfentanil'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morphine</strong> – <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">Morphine</a> is the prototype opioid agent. It is less lipophilic than the synthetic opioids (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>, <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>, <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a>), which results in slower onset of action (within 20 minutes) due to poor penetration of the blood-brain barrier. Because of its long analgesic duration of four to five hours, morphine is often selected to preemptively and/or urgently control postoperative pain. (See <a class="local">'Morphine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydromorphone</strong> – <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">Hydromorphone</a> is a semi-synthetic <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> derivative that is approximately five times more potent than morphine and has a slightly more rapid onset (peak effect within 10 minutes after IV administration), and a shorter half-life of 2.4 hours. Hydromorphone is sometimes selected to provide supplemental analgesia with either an inhalation anesthetic or a TIVA technique. Small boluses of hydromorphone may be administered near the end of surgery to control postoperative pain with greater analgesic efficacy and less respiratory depression compared with morphine. (See <a class="local">'Hydromorphone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methadone</strong> – <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> has a unique mechanism of action via agonism of the mu-opioid receptor as well as antagonism at N-methyl-D-aspartate (NMDA) receptors and inhibition of serotonin and norepinephrine reuptake in the central nervous system. Onset of analgesia may occur within eight minutes, but duration may extend to 24 to 36 hours when doses exceed the redistribution half-life (approximately 20 mg). Thus, methadone may be administered as a single IV dose during induction of anesthesia to provide analgesia through the intraoperative and postoperative periods. If methadone is administered to treat acute postoperative pain, close monitoring is necessary due to its extended half-life. (See <a class="local">'Methadone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meperidine</strong> – <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">Meperidine</a> is most commonly used to treat perioperative shivering at doses of 12.5 to 25 mg. Use for perioperative analgesia is generally avoided due to its high risk for adverse effects (eg, central nervous system excitatory effects [anxiety, hyperreflexia, myoclonus, seizures] due to its active metabolite normeperidine; serotonin and norepinephrine reuptake inhibition; anticholinergic effects; severe reactions in patients taking monoamine oxidase inhibitors [MAOIs]; high abuse potential), as well as its relative lack of efficacy compared with other opioids. (See <a class="local">'Meperidine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nalbuphine</strong> – <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">Nalbuphine</a> is a phenanthrene synthetic opioid with agonist-antagonist actions. It is used to provide perioperative analgesia with a potency equivalent to <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> because of its kappa-opioid receptor agonist action. Sub-analgesic dosing is used to treat opioid-related adverse effects (eg, pruritus, urinary retention, respiratory depression) without compromising analgesia. Nalbuphine may precipitate opioid withdrawal in opioid tolerant patients taking mu-opioid receptor agonists. (See <a class="local">'Nalbuphine'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Smith C, McEwan AI, Jhaveri R, et al. The interaction of fentanyl on the Cp50 of propofol for loss of consciousness and skin incision. Anesthesiology 1994; 81:820.</a></li><li><a class="nounderline abstract_t">Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology 1991; 74:53.</a></li><li><a class="nounderline abstract_t">Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992; 76:334.</a></li><li><a class="nounderline abstract_t">Miller TE, Gan TJ. Total intravenous anesthesia and anesthetic outcomes. J Cardiothorac Vasc Anesth 2015; 29 Suppl 1:S11.</a></li><li><a class="nounderline abstract_t">Kim JE, Min SK, Chae YJ, et al. Pharmacological and nonpharmacological prevention of fentanyl-induced cough: a meta-analysis. J Anesth 2014; 28:257.</a></li><li><a class="nounderline abstract_t">Uvelin A, Rakic G. Guidelines for prevention of fentanyl-induced cough. Acta Anaesthesiol Scand 2009; 53:1228.</a></li><li><a class="nounderline abstract_t">Levin TT, Bakr MH, Nikolova T. Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction. Gen Hosp Psychiatry 2010; 32:648.e9.</a></li><li><a class="nounderline abstract_t">Cambic CR, Avram MJ, Gupta DK, Wong CA. Effect of ritonavir-induced cytochrome P450 3A4 inhibition on plasma fentanyl concentrations during patient-controlled epidural labor analgesia: a pharmacokinetic simulation. Int J Obstet Anesth 2014; 23:45.</a></li><li><a class="nounderline abstract_t">Björkman S, Stanski DR, Harashima H, et al. Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model. J Pharmacokinet Biopharm 1993; 21:255.</a></li><li><a class="nounderline abstract_t">Gelberg J, Jonmarker C, Stenqvist O, Werner O. Intravenous boluses of fentanyl, 1 μg kg⁻¹, and remifentanil, 0.5 μg kg⁻¹, give similar maximum ventilatory depression in awake volunteers. Br J Anaesth 2012; 108:1028.</a></li><li class="breakAll">Stoelting R, Miller RD. Opioids. In: Basics of Anesthesia, 5th ed, Elsevier, Philadelphia 2007.</li><li class="breakAll">Johnson KB, Healy A. The clinical pharmacology of opioids. In: Clinical Pharmacology for Anesthesiology, McGraw-Hill, New York 2014.</li><li><a class="nounderline abstract_t">Beers R, Camporesi E. Remifentanil update: clinical science and utility. CNS Drugs 2004; 18:1085.</a></li><li><a class="nounderline abstract_t">Mertens MJ, Olofsen E, Engbers FH, et al. Propofol reduces perioperative remifentanil requirements in a synergistic manner: response surface modeling of perioperative remifentanil-propofol interactions. Anesthesiology 2003; 99:347.</a></li><li><a class="nounderline abstract_t">Manyam SC, Gupta DK, Johnson KB, et al. Opioid-volatile anesthetic synergy: a response surface model with remifentanil and sevoflurane as prototypes. Anesthesiology 2006; 105:267.</a></li><li><a class="nounderline abstract_t">Lang E, Kapila A, Shlugman D, et al. Reduction of isoflurane minimal alveolar concentration by remifentanil. Anesthesiology 1996; 85:721.</a></li><li><a class="nounderline abstract_t">Kapila A, Glass PS, Jacobs JR, et al. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology 1995; 83:968.</a></li><li><a class="nounderline abstract_t">Berger M, Philips-Bute B, Guercio J, et al. A novel application for bolus remifentanil: blunting the hemodynamic response to Mayfield skull clamp placement. Curr Med Res Opin 2014; 30:243.</a></li><li><a class="nounderline abstract_t">Joshi GP, Jamerson BD, Roizen MF, et al. Is there a learning curve associated with the use of remifentanil? Anesth Analg 2000; 91:1049.</a></li><li><a class="nounderline abstract_t">Sajedi P, Rahimian A, Khalili G. Comparative evaluation between two methods of induced hypotension with infusion of Remifentanil and Labetalol during sinus endoscopy. J Res Pharm Pract 2016; 5:264.</a></li><li><a class="nounderline abstract_t">Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000; 93:409.</a></li><li><a class="nounderline abstract_t">Echevarría G, Elgueta F, Fierro C, et al. Nitrous oxide (N(2)O) reduces postoperative opioid-induced hyperalgesia after remifentanil-propofol anaesthesia in humans. Br J Anaesth 2011; 107:959.</a></li><li><a class="nounderline abstract_t">Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005; 103:147.</a></li><li><a class="nounderline abstract_t">Yu EH, Tran DH, Lam SW, Irwin MG. Remifentanil tolerance and hyperalgesia: short-term gain, long-term pain? Anaesthesia 2016; 71:1347.</a></li><li><a class="nounderline abstract_t">Angst MS. Intraoperative Use of Remifentanil for TIVA: Postoperative Pain, Acute Tolerance, and Opioid-Induced Hyperalgesia. J Cardiothorac Vasc Anesth 2015; 29 Suppl 1:S16.</a></li><li><a class="nounderline abstract_t">Kars MS, Villacres Mori B, Ahn S, et al. Fentanyl versus remifentanil-based TIVA for pediatric scoliosis repair: does it matter? Reg Anesth Pain Med 2019; 44:627.</a></li><li><a class="nounderline abstract_t">Hoshijima H, Takeuchi R, Kuratani N, et al. Incidence of postoperative shivering comparing remifentanil with other opioids: a meta-analysis. J Clin Anesth 2016; 32:300.</a></li><li class="breakAll">Ultiva [package insert]. Canonsburg, PA: Mylan; 2015.</li><li><a class="nounderline abstract_t">Halliburton JR. The pharmacokinetics of fentanyl, sufentanil and alfentanil: a comparative review. AANA J 1988; 56:229.</a></li><li><a class="nounderline abstract_t">Maciejewski D. Sufentanil in anaesthesiology and intensive therapy. Anaesthesiol Intensive Ther 2012; 44:35.</a></li><li><a class="nounderline abstract_t">Djian MC, Blanchet B, Pesce F, et al. Comparison of the time to extubation after use of remifentanil or sufentanil in combination with propofol as anesthesia in adults undergoing nonemergency intracranial surgery: a prospective, randomized, double-blind trial. Clin Ther 2006; 28:560.</a></li><li><a class="nounderline abstract_t">Bennett JA, Abrams JT, Van Riper DF, Horrow JC. Difficult or impossible ventilation after sufentanil-induced anesthesia is caused primarily by vocal cord closure. Anesthesiology 1997; 87:1070.</a></li><li><a class="nounderline abstract_t">Gravlee GP, Ramsey FM, Roy RC, et al. Rapid administration of a narcotic and neuromuscular blocker: a hemodynamic comparison of fentanyl, sufentanil, pancuronium, and vecuronium. Anesth Analg 1988; 67:39.</a></li><li><a class="nounderline abstract_t">Philbin DM, Rosow CE, Schneider RC, et al. Fentanyl and sufentanil anesthesia revisited: how much is enough? Anesthesiology 1990; 73:5.</a></li><li class="breakAll">Sufentanil Citrate [package insert]. Lake Forest, IL: Hospira; 2014.</li><li><a class="nounderline abstract_t">Lötsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005; 29:S90.</a></li><li><a class="nounderline abstract_t">Saari TI, Laine K, Leino K, et al. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther 2006; 80:502.</a></li><li><a class="nounderline abstract_t">Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009; 38:426.</a></li><li><a class="nounderline abstract_t">Palmer PP, Royal MA, Miller RD. Novel delivery systems for postoperative analgesia. Best Pract Res Clin Anaesthesiol 2014; 28:81.</a></li><li><a class="nounderline abstract_t">Jain AK, Kumar S, Tyagi A. Practice trends in use of morphine for control of intraoperative pain: An audit. J Anaesthesiol Clin Pharmacol 2012; 28:62.</a></li><li class="breakAll">Morphine Sulfate [package insert]. Lake Forest, IL: Hospira; 2011.</li><li><a class="nounderline abstract_t">Aubrun F, Amour J, Rosenthal D, et al. Effects of a loading dose of morphine before i.v. morphine titration for postoperative pain relief: a randomized, double-blind, placebo-control study. Br J Anaesth 2007; 98:124.</a></li><li><a class="nounderline abstract_t">Aubrun F, Mazoit JX, Riou B. Postoperative intravenous morphine titration. Br J Anaesth 2012; 108:193.</a></li><li><a class="nounderline abstract_t">Peterson GM, Randall CT, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 1990; 38:121.</a></li><li><a class="nounderline abstract_t">Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251:477.</a></li><li><a class="nounderline abstract_t">MacKenzie M, Zed PJ, Ensom MH. Opioid Pharmacokinetics-Pharmacodynamics: Clinical Implications in Acute Pain Management in Trauma. Ann Pharmacother 2016; 50:209.</a></li><li><a class="nounderline abstract_t">Felden L, Walter C, Harder S, et al. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. Br J Anaesth 2011; 107:319.</a></li><li><a class="nounderline abstract_t">Meissner K, Dahan A, Olofsen E, et al. Morphine and Hydromorphone Effects, Side Effects, and Variability: A Crossover Study in Human Volunteers. Anesthesiology 2023; 139:16.</a></li><li><a class="nounderline abstract_t">Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001; 9:84.</a></li><li><a class="nounderline abstract_t">Jeleazcov C, Saari TI, Ihmsen H, et al. Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. Anesthesiology 2014; 120:378.</a></li><li><a class="nounderline abstract_t">Lohela TJ, Poikola S, Neuvonen M, et al. Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers. Anesth Analg 2021; 133:423.</a></li><li><a class="nounderline abstract_t">Davison SN, Mayo PR. Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. J Opioid Manag 2008; 4:335.</a></li><li><a class="nounderline abstract_t">Machado FC, Vieira JE, de Orange FA, Ashmawi HA. Intraoperative Methadone Reduces Pain and Opioid Consumption in Acute Postoperative Pain: A Systematic Review and Meta-analysis. Anesth Analg 2019; 129:1723.</a></li><li><a class="nounderline abstract_t">Tognoli E, Proto PL, Motta G, et al. Methadone for postoperative analgesia: contribution of N-methyl-D-aspartate receptor antagonism: A randomised controlled trial. Eur J Anaesthesiol 2020; 37:934.</a></li><li><a class="nounderline abstract_t">Kharasch ED. Intraoperative methadone: rediscovery, reappraisal, and reinvigoration? Anesth Analg 2011; 112:13.</a></li><li><a class="nounderline abstract_t">Murphy GS, Szokol JW. Intraoperative Methadone in Surgical Patients: A Review of Clinical Investigations. Anesthesiology 2019; 131:678.</a></li><li><a class="nounderline abstract_t">Myles PS, Brummett CM. Consideration of Methadone as an Analgesic Option for Short-stay Surgery. Anesthesiology 2023; 139:374.</a></li><li><a class="nounderline abstract_t">D'Souza RS, Gurrieri C, Johnson RL, et al. Intraoperative methadone administration and postoperative pain control: a systematic review and meta-analysis. Pain 2020; 161:237.</a></li><li><a class="nounderline abstract_t">Pontes JPJ, Braz FR, Módolo NSP, et al. Intra-operative methadone effect on quality of recovery compared with morphine following laparoscopic gastroplasty: a randomised controlled trial. Anaesthesia 2021; 76:199.</a></li><li><a class="nounderline abstract_t">Komen H, Brunt LM, Deych E, et al. Intraoperative Methadone in Same-Day Ambulatory Surgery: A Randomized, Double-Blinded, Dose-Finding Pilot Study. Anesth Analg 2019; 128:802.</a></li><li><a class="nounderline abstract_t">Bastian K, Buehler PK, Slizyte D, et al. A preoperative single dose of methadone for moderate-to-severely painful surgery reduces postoperative morphine consumption. Minerva Anestesiol 2019; 85:1053.</a></li><li><a class="nounderline abstract_t">Jin Z, Lin EJ, He Y, Lin J. Intraoperative methadone for postoperative pain management - systematic review protocol. Int J Physiol Pathophysiol Pharmacol 2019; 11:220.</a></li><li><a class="nounderline abstract_t">Machado FC, Palmeira CCA, Torres JNL, et al. Intraoperative use of methadone improves control of postoperative pain in morbidly obese patients: a randomized controlled study. J Pain Res 2018; 11:2123.</a></li><li><a class="nounderline abstract_t">Murphy GS, Szokol JW, Avram MJ, et al. Clinical Effectiveness and Safety of Intraoperative Methadone in Patients Undergoing Posterior Spinal Fusion Surgery: A Randomized, Double-blinded, Controlled Trial. Anesthesiology 2017; 126:822.</a></li><li><a class="nounderline abstract_t">Gottschalk A, Durieux ME, Nemergut EC. Intraoperative methadone improves postoperative pain control in patients undergoing complex spine surgery. Anesth Analg 2011; 112:218.</a></li><li><a class="nounderline abstract_t">Murphy GS, Avram MJ, Greenberg SB, et al. Postoperative Pain and Analgesic Requirements in the First Year after Intraoperative Methadone for Complex Spine and Cardiac Surgery. Anesthesiology 2020; 132:330.</a></li><li><a class="nounderline abstract_t">Kharasch ED, Avram MJ, Clark JD. Rational Perioperative Opioid Management in the Era of the Opioid Crisis. Anesthesiology 2020; 132:603.</a></li><li><a class="nounderline abstract_t">Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 1995; 274:1263.</a></li><li><a class="nounderline abstract_t">Durand RP, Levine JH, Lichtenstein LS, et al. Teachers' perceptions concerning the relative values of personal and clinical characteristics and their influence on the assignment of students' clinical grades. Med Educ 1988; 22:335.</a></li><li><a class="nounderline abstract_t">Dunn LK, Yerra S, Fang S, et al. Safety profile of intraoperative methadone for analgesia after major spine surgery: An observational study of 1,478 patients. J Opioid Manag 2018; 14:83.</a></li><li><a class="nounderline abstract_t">Alinejad S, Kazemi T, Zamani N, et al. A systematic review of the cardiotoxicity of methadone. EXCLI J 2015; 14:577.</a></li><li><a class="nounderline abstract_t">Greenblatt DJ. Drug interactions with methadone: Time to revise the product label. Clin Pharmacol Drug Dev 2014; 3:249.</a></li><li><a class="nounderline abstract_t">Totah RA, Sheffels P, Roberts T, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008; 108:363.</a></li><li><a class="nounderline abstract_t">Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. Am J Ther 2002; 9:53.</a></li><li><a class="nounderline abstract_t">Weiner AL. Meperidine as a potential cause of serotonin syndrome in the emergency department. Acad Emerg Med 1999; 6:156.</a></li><li><a class="nounderline abstract_t">Sangarlangkarn S, Klaewtanong V, Jonglerttrakool P, Khankaew V. Meperidine as a spinal anesthetic agent: a comparison with lidocaine-glucose. Anesth Analg 1987; 66:235.</a></li><li><a class="nounderline abstract_t">Woodhouse A, Hobbes AFT, Mather LE, Gibson M. A comparison of morphine, pethidine and fentanyl in the postsurgical patient-controlled analgesia environment. Pain 1996; 64:115.</a></li><li><a class="nounderline abstract_t">Horn EP, Standl T, Sessler DI, et al. Physostigmine prevents postanesthetic shivering as does meperidine or clonidine. Anesthesiology 1998; 88:108.</a></li><li><a class="nounderline abstract_t">Jayaraj A, Balachander H, Kuppusamy SK, et al. Comparison of meperidine, tramadol and fentanyl for post-spinal shivering prevention during cesarean delivery: A double-blind randomized controlled trial. J Obstet Gynaecol Res 2019; 45:2202.</a></li><li><a class="nounderline abstract_t">Yu G, Jin S, Chen J, et al. The effects of novel α2-adrenoreceptor agonist dexmedetomidine on shivering in patients underwent caesarean section. Biosci Rep 2019; 39.</a></li><li><a class="nounderline abstract_t">Liu J, Wang Y, Ma W. Shivering prevention and treatment during cesarean delivery under neuraxial anesthesia: a systematic review. Minerva Anestesiol 2018; 84:1393.</a></li><li><a class="nounderline abstract_t">Ching Wong SS, Cheung CW. Analgesic Efficacy and Adverse Effects of Meperidine in Managing Postoperative or Labor Pain: A Narrative Review of Randomized Controlled Trials. Pain Physician 2020; 23:175.</a></li><li><a class="nounderline abstract_t">Buck ML. Is Meperidine the Drug That Just Won't Die? J Pediatr Pharmacol Ther 2011; 16:167.</a></li><li><a class="nounderline abstract_t">Koren G, Maurice L. Pediatric uses of opioids. Pediatr Clin North Am 1989; 36:1141.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics. Committee on Psychosocial Aspects of Child and Family Health, Task Force on Pain in Infants, Children, and Adolescents. The assessment and management of acute pain in infants, children, and adolescents. Pediatrics 2001; 108:793.</a></li><li><a class="nounderline abstract_t">Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13:180.</a></li><li><a class="nounderline abstract_t">Szeto HH, Inturrisi CE, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med 1977; 86:738.</a></li><li class="breakAll">Demerol (meperidine hydrochloride, USP). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/005010s051lbl.pdf (Accessed on July 15, 2021).</li><li><a class="nounderline abstract_t">Pond SM, Tong T, Benowitz NL, et al. Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. Clin Pharmacol Ther 1981; 30:183.</a></li><li><a class="nounderline abstract_t">Verbeeck RK, Branch RA, Wilkinson GR. Meperidine disposition in man: influence of urinary pH and route of administration. Clin Pharmacol Ther 1981; 30:619.</a></li><li><a class="nounderline abstract_t">Mather LE, Meffin PJ. Clinical pharmacokinetics of pethidine. Clin Pharmacokinet 1978; 3:352.</a></li><li><a class="nounderline abstract_t">Jiraki K. Lethal effects of normeperidine. Am J Forensic Med Pathol 1992; 13:42.</a></li><li class="breakAll">NUBAIN (nalbuphine hydrochloride). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018024s040lbl.pdf (Accessed on July 15, 2021).</li><li><a class="nounderline abstract_t">Davis MP, Fernandez C, Regel S, McPherson ML. Does nalbuphine have a niche in managing pain? J Opioid Manag 2018; 14:143.</a></li><li><a class="nounderline abstract_t">Zacny JP, Conley K, Marks S. Comparing the subjective, psychomotor and physiological effects of intravenous nalbuphine and morphine in healthy volunteers. J Pharmacol Exp Ther 1997; 280:1159.</a></li><li><a class="nounderline abstract_t">Mora A, López C, Dabhi G, et al. Extraintestinal pathogenic Escherichia coli O1:K1:H7/NM from human and avian origin: detection of clonal groups B2 ST95 and D ST59 with different host distribution. BMC Microbiol 2009; 9:132.</a></li><li><a class="nounderline abstract_t">Yeh YC, Lin TF, Lin FS, et al. Combination of opioid agonist and agonist-antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain. Br J Anaesth 2008; 101:542.</a></li><li><a class="nounderline abstract_t">Latasch L, Teichmüller T, Dudziak R, Probst S. Antagonisation of fentanyl-induced respiratory depression by nalbuphine. Acta Anaesthesiol Belg 1989; 40:35.</a></li><li><a class="nounderline abstract_t">Jannuzzi RG. Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature. Clin J Pain 2016; 32:87.</a></li><li><a class="nounderline abstract_t">Mathai F, Portugal F, Mehta Z, Davis M. Nalbuphine #381. J Palliat Med 2019; 22:1471.</a></li><li><a class="nounderline abstract_t">Wang HJ, Hsiong CH, Ho ST, et al. Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans. Pharm Res 2014; 31:1676.</a></li><li><a class="nounderline abstract_t">Hawi A, Alcorn H Jr, Berg J, et al. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol 2015; 16:47.</a></li></ol></div><div id="topicVersionRevision">Topic 130113 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7943832" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The interaction of fentanyl on the Cp50 of propofol for loss of consciousness and skin incision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1824743" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pharmacokinetics, pharmacodynamics, and rational opioid selection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1539843" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26025040" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Total intravenous anesthesia and anesthetic outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23958914" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pharmacological and nonpharmacological prevention of fentanyl-induced cough: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19737187" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Guidelines for prevention of fentanyl-induced cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21112467" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24333052" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of ritonavir-induced cytochrome P450 3A4 inhibition on plasma fentanyl concentrations during patient-controlled epidural labor analgesia: a pharmacokinetic simulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8258767" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22440314" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Intravenous boluses of fentanyl, 1μg kg⁻¹, and remifentanil, 0.5μg kg⁻¹, give similar maximum ventilatory depression in awake volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22440314" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Intravenous boluses of fentanyl, 1μg kg⁻¹, and remifentanil, 0.5μg kg⁻¹, give similar maximum ventilatory depression in awake volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22440314" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Intravenous boluses of fentanyl, 1μg kg⁻¹, and remifentanil, 0.5μg kg⁻¹, give similar maximum ventilatory depression in awake volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15581380" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Remifentanil update: clinical science and utility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12883407" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Propofol reduces perioperative remifentanil requirements in a synergistic manner: response surface modeling of perioperative remifentanil-propofol interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871060" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Opioid-volatile anesthetic synergy: a response surface model with remifentanil and sevoflurane as prototypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8873541" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Reduction of isoflurane minimal alveolar concentration by remifentanil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7486182" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Measured context-sensitive half-times of remifentanil and alfentanil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24161010" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A novel application for bolus remifentanil: blunting the hemodynamic response to Mayfield skull clamp placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11049882" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Is there a learning curve associated with the use of remifentanil?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27843963" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparative evaluation between two methods of induced hypotension with infusion of Remifentanil and Labetalol during sinus endoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10910490" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21965050" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nitrous oxide (N(2)O) reduces postoperative opioid-induced hyperalgesia after remifentanil-propofol anaesthesia in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983467" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27734470" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Remifentanil tolerance and hyperalgesia: short-term gain, long-term pain?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26025041" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intraoperative Use of Remifentanil for TIVA: Postoperative Pain, Acute Tolerance, and Opioid-Induced Hyperalgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30923248" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fentanyl versus remifentanil-based TIVA for pediatric scoliosis repair: does it matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26432635" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Incidence of postoperative shivering comparing remifentanil with other opioids: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26432635" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Incidence of postoperative shivering comparing remifentanil with other opioids: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2970761" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The pharmacokinetics of fentanyl, sufentanil and alfentanil: a comparative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23801512" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sufentanil in anaesthesiology and intensive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16750467" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of the time to extubation after use of remifentanil or sufentanil in combination with propofol as anesthesia in adults undergoing nonemergency intracranial surgery: a prospective, randomized, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366458" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Difficult or impossible ventilation after sufentanil-induced anesthesia is caused primarily by vocal cord closure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2892437" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rapid administration of a narcotic and neuromuscular blocker: a hemodynamic comparison of fentanyl, sufentanil, pancuronium, and vecuronium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2141773" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fentanyl and sufentanil anesthesia revisited: how much is enough?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2141773" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fentanyl and sufentanil anesthesia revisited: how much is enough?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15907650" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pharmacokinetic-pharmacodynamic modeling of opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17112806" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19735903" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Opioid rotation: the science and the limitations of the equianalgesic dose table.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24815968" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Novel delivery systems for postoperative analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22345948" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Practice trends in use of morphine for control of intraoperative pain: An audit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22345948" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Practice trends in use of morphine for control of intraoperative pain: An audit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17065166" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effects of a loading dose of morphine before i.v. morphine titration for postoperative pain relief: a randomized, double-blind, placebo-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22250276" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Postoperative intravenous morphine titration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2338107" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2810109" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26739277" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Opioid Pharmacokinetics-Pharmacodynamics: Clinical Implications in Acute Pain Management in Trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21841049" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Comparative clinical effects of hydromorphone and morphine: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37014986" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Morphine and Hydromorphone Effects, Side Effects, and Variability: A Crossover Study in Human Volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11305075" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hydromorphone: pharmacology and clinical applications in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23958818" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33177323" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19192761" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31743194" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Intraoperative Methadone Reduces Pain and Opioid Consumption in Acute Postoperative Pain: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32516227" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Methadone for postoperative analgesia: contribution of N-methyl-D-aspartate receptor antagonism: A randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21173206" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Intraoperative methadone: rediscovery, reappraisal, and reinvigoration?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31094758" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intraoperative Methadone in Surgical Patients: A Review of Clinical Investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37698432" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Consideration of Methadone as an Analgesic Option for Short-stay Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613867" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Intraoperative methadone administration and postoperative pain control: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32803791" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Intra-operative methadone effect on quality of recovery compared with morphine following laparoscopic gastroplasty: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29847382" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Intraoperative Methadone in Same-Day Ambulatory Surgery: A Randomized, Double-Blinded, Dose-Finding Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31106550" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A preoperative single dose of methadone for moderate-to-severely painful surgery reduces postoperative morphine consumption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31777646" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Intraoperative methadone for postoperative pain management - systematic review protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30323647" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Intraoperative use of methadone improves control of postoperative pain in morbidly obese patients: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28418966" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical Effectiveness and Safety of Intraoperative Methadone in Patients Undergoing Posterior Spinal Fusion Surgery: A Randomized, Double-blinded, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20418538" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Intraoperative methadone improves postoperative pain control in patients undergoing complex spine surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31939849" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Postoperative Pain and Analgesic Requirements in the First Year after Intraoperative Methadone for Complex Spine and Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32058348" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Rational Perioperative Opioid Management in the Era of the Opioid Crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7562497" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3173162" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Teachers' perceptions concerning the relative values of personal and clinical characteristics and their influence on the assignment of students' clinical grades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29733094" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Safety profile of intraoperative methadone for analgesia after major spine surgery: An observational study of 1,478 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26869865" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A systematic review of the cardiotoxicity of methadone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27128829" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Drug interactions with methadone: Time to revise the product label.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18292673" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Role of CYP2B6 in stereoselective human methadone metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11782820" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Meperidine: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10051909" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Meperidine as a potential cause of serotonin syndrome in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3548485" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Meperidine as a spinal anesthetic agent: a comparison with lidocaine-glucose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8867253" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A comparison of morphine, pethidine and fentanyl in the postsurgical patient-controlled analgesia environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9447863" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Physostigmine prevents postanesthetic shivering as does meperidine or clonidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31486253" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Comparison of meperidine, tramadol and fentanyl for post-spinal shivering prevention during cesarean delivery: A double-blind randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30643009" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The effects of novelα2-adrenoreceptor agonist dexmedetomidine on shivering in patients underwent caesarean section.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29945433" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Shivering prevention and treatment during cesarean delivery under neuraxial anesthesia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32214301" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Analgesic Efficacy and Adverse Effects of Meperidine in Managing Postoperative or Labor Pain: A Narrative Review of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22479158" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Is Meperidine the Drug That Just Won't Die?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2552385" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pediatric uses of opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533354" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The assessment and management of acute pain in infants, children, and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6187275" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Central nervous system excitatory effects of meperidine in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/869353" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/869353" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7249503" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7297021" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Meperidine disposition in man: influence of urinary pH and route of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/359212" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinical pharmacokinetics of pethidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1585886" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Lethal effects of normeperidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1585886" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Lethal effects of normeperidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29733100" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Does nalbuphine have a niche in managing pain?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9067299" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Comparing the subjective, psychomotor and physiological effects of intravenous nalbuphine and morphine in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19583828" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Extraintestinal pathogenic Escherichia coli O1:K1:H7/NM from human and avian origin: detection of clonal groups B2 ST95 and D ST59 with different host distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18640992" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Combination of opioid agonist and agonist-antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2499159" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Antagonisation of fentanyl-induced respiratory depression by nalbuphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26650717" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31661394" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Nalbuphine #381.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24526241" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25885112" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
